Financial Performance - Climb Bio reported cash, cash equivalents, and marketable securities of $197.8 million as of March 31, 2025, expected to fund operations through 2027[8] - Research and Development (R&D) expenses for Q1 2025 were $17.3 million, significantly up from $1.1 million in Q1 2024[8] - General and Administrative (G&A) expenses for Q1 2025 were $5.7 million, compared to $1.9 million in the same period last year[8] - The net loss for Q1 2025 was $20.8 million, compared to a net loss of $1.7 million in Q1 2024, resulting in a net loss per share of $0.31[8] Clinical Trials and Regulatory Approvals - Climb Bio received FDA clearance for a Phase 2 clinical trial of budoprutug in primary membranous nephropathy (pMN) and a Phase 1b/2a trial in immune thrombocytopenia (ITP) in March 2025[4] - The company plans to initiate clinical studies for budoprutug in ITP and systemic lupus erythematosus (SLE) in the coming weeks, with pMN studies expected to start in the second half of 2025[3] - Climb Bio is advancing the CLYM116 program, with plans to submit an investigational new drug (IND) or clinical trial application (CTA) by year-end 2025[3] - The company is pursuing regulatory clearance for budoprutug clinical trials outside the U.S. for SLE, indicating a strategy for international market expansion[4] Leadership and Organizational Changes - The company appointed Kim Cobleigh Drapkin and Bo Cumbo as Independent Directors and Perrin Wilson, Ph.D., as Chief Business Officer in 2025[8] Product Pipeline - Climb Bio's pipeline includes budoprutug and CLYM116, targeting immune-mediated diseases with significant therapeutic potential[7]
Eliem Therapeutics(ELYM) - 2025 Q1 - Quarterly Results